Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) AI Stock Analysis

• Market Cap: HK$5.35B
• Dividend Yield: 0.96%
• Average Volume (3M): 30.51K
• Price to Earnings (P/E): 25.9
• Beta (1Y): 0.04
• Revenue Growth: 14.06%
• EPS Growth: 3.02%
• Country: HK
• Employees: 1,735
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.62
• Shares Outstanding: 104,213,394
• 10 Day Avg. Volume: 32,620
• 30 Day Avg. Volume: 30,506
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$37.00
• Price Target Upside: 18.97% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 73 Outperform
• Price Target: HK$37.00 ▲(18.97% Upside)

Shanghai Kindly Medical Instruments Co., Ltd. Class H has a strong financial foundation with robust revenue growth and profitability, which is the most significant factor in its score. Technical analysis suggests caution due to overbought signals, and valuation metrics indicate fair pricing. The absence of earnings call and corporate events data means these factors do not influence the score.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Kindly Medical Instruments Co., Ltd. Class H (1501) is a Chinese company that specializes in the development, manufacturing, and distribution of medical devices. The company primarily focuses on providing high-quality, innovative products in the cardiovascular and peripheral vascular fields. Its core products include disposable medical devices such as catheters, guide wires, and related accessories, which are essential in various surgical and medical procedures.

How the Company Makes Money

Shanghai Kindly Medical Instruments Co., Ltd. generates revenue through the sale of its medical devices, which are used in hospitals, clinics, and other healthcare settings. The company's key revenue streams include domestic sales within China and international exports to various countries, leveraging its strong distribution network. Additionally, the company may engage in strategic partnerships or collaborations with other medical institutions or healthcare providers, enhancing its market reach and product offerings. The company also invests in research and development to innovate and improve its product lines, maintaining a competitive edge in the medical device industry.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Kindly Medical Instruments Co., Ltd. Class H shows strong financial performance with robust revenue growth and profitability margins. The balance sheet is solid with low leverage and a strong equity base, reducing financial risk. However, cash flow efficiency needs improvement, which slightly tempers the overall financial score.

Income Statement

Shanghai Kindly Medical Instruments Co., Ltd. Class H has demonstrated strong income statement performance with a consistent upward trajectory in revenue growth, showing an impressive revenue growth rate from 2023 to 2024 at 13.15%. Gross profit margin remains robust at approximately 63.11%, indicating effective cost management. The net profit margin also improved, reaching 22.53% in 2024, reflecting enhanced profitability. The company maintains healthy EBIT and EBITDA margins at 25.38% and 29.98%, respectively, showcasing operational efficiency. The key strength lies in sustained revenue growth and high profitability margins, although the company should monitor any future fluctuations in margins.

Balance Sheet

The balance sheet of Shanghai Kindly Medical Instruments Co., Ltd. Class H reveals a strong financial position with an equity ratio of 78.51% in 2024, indicating a solid equity base relative to total assets. The debt-to-equity ratio remains low at 0.14, suggesting minimal leverage and reduced financial risk. Return on equity improved to 10.82%, reflecting enhanced returns for shareholders. The company benefits from a strong equity position and low leverage, which contributes to financial stability and mitigates risk.

Cash Flow

Cash flow analysis for Shanghai Kindly Medical Instruments Co., Ltd. Class H shows areas for improvement. The operating cash flow to net income ratio is low due to operating cash flow being unavailable in 2024. Free cash flow remains a concern with fluctuations observed in prior years, indicating potential challenges in cash generation from operations. However, the company has managed to maintain a positive free cash flow in earlier periods, suggesting potential for recovery in cash flow generation. Focus should be placed on enhancing cash flow efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	851.95M	752.84M	585.88M	464.68M	358.43M
Gross Profit	537.66M	438.07M	332.49M	275.75M	234.41M
EBITDA	255.43M	225.88M	159.99M	168.81M	143.23M
Net Income	191.91M	156.46M	131.71M	142.96M	121.35M
Balance Sheet
Total Assets	2.26B	2.03B	1.83B	1.62B	1.42B
Cash, Cash Equivalents and Short-Term Investments	554.51M	434.40M	528.27M	640.55M	941.59M
Total Debt	243.69M	94.78M	48.83M	13.40M	1.73M
Total Liabilities	473.39M	351.25M	273.23M	183.63M	95.04M
Stockholders Equity	1.77B	1.65B	1.51B	1.40B	1.31B
Cash Flow
Free Cash Flow	59.80M	-53.05M	-62.75M	-205.07M	7.92M
Operating Cash Flow	225.54M	178.15M	180.46M	72.76M	95.71M
Investing Cash Flow	-187.31M	-283.81M	-316.18M	-268.08M	-221.87M
Financing Cash Flow	56.97M	8.06M	9.72M	-31.07M	-27.95M

Shanghai Kindly Medical Instruments Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 31.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1501, the sentiment is Neutral. The current price of 31.1 is below the 20-day moving average (MA) of 31.93, above the 50-day MA of 30.27, and above the 200-day MA of 27.38, indicating a neutral trend. The MACD of -0.09 indicates Positive momentum. The RSI at 43.22 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1501.

Shanghai Kindly Medical Instruments Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9997	83 Outperform	HK$10.45B	17.21	22.12%	2.95%	6.51%	4.85%
1358	76 Outperform	HK$2.32B	15.00	3.80%	6.24%	21.39%	-0.57%
3600	74 Outperform	HK$4.85B	10.21	15.02%	3.83%	6.87%	18.37%
1501	73 Outperform	HK$5.35B	25.85	10.31%	0.96%	14.06%	3.02%
2276	67 Neutral	HK$19.52B	33.78	27.01%	0.83%	13.58%	24.59%
0876	45 Neutral	HK$277.32M	-8.87	―	―	-8.46%	45.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Shanghai Kindly Medical Instruments Co., Ltd. Class H Corporate Events

Shanghai Kindly Medical Instruments Establishes Huaige Guangtai Fund for Medical Device Investments

Shanghai Kindly Medical Instruments Co., Ltd. has entered into a Partnership Agreement to establish the Huaige Guangtai Fund, with a capital commitment of up to RMB110 million. This fund aims to achieve returns through equity investments in medical device companies, potentially strengthening the company’s market position and investment portfolio.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments to Discuss Share Issuance Mandate at 2025 EGM

Shanghai Kindly Medical Instruments Co., Ltd. has announced the convening of its first extraordinary general meeting of 2025 to discuss a special resolution. The resolution seeks to grant the Board a general mandate to issue additional Domestic and/or H Shares, not exceeding 20% of the total issued shares, to enhance the company’s capital structure and support its growth strategies.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai INT Medical Instruments Updates Supervisor Emoluments

Shanghai INT Medical Instruments Co., Ltd. has released a supplemental announcement detailing the emoluments paid to its supervisors from 2019 to 2024. The announcement clarifies that the emoluments were paid in their capacity as employees of the group, not as supervisors, and does not alter any other information in the company’s annual reports.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai INT Medical Instruments Co., Ltd. Announces AGM Results and Board Appointments

Shanghai INT Medical Instruments Co., Ltd., a company incorporated in China, held its annual general meeting for 2024 on May 23, 2025. The meeting, chaired by Dr. Liang Dongke, resulted in the approval of all resolutions, including the re-election and appointment of directors and supervisors, and the election of the chairman for the fourth session of the board and supervisory committee. The unanimous approval of the company’s reports and financial statements reflects strong shareholder support and positions the company for continued stability and governance.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments Announces Board Composition

Shanghai Kindly Medical Instruments Co., Ltd. has announced the composition of its board of directors, detailing the roles and functions of each member. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and decision-making processes, which could influence stakeholders’ perspectives on the company’s future operations.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.

Shanghai Kindly Medical Instruments to Acquire Controlling Stake in Target Company

Shanghai Kindly Medical Instruments Co., Ltd., a company incorporated in the People’s Republic of China, has entered into a Formal Acquisition Agreement to acquire a controlling stake in a target company. The acquisition involves purchasing 81.83% equity interest in the target company for approximately RMB512.84 million, with Shanghai Kindly Medical Instruments acquiring a 51.70% controlling stake. This transaction will result in the target company becoming a non-wholly owned subsidiary, and further capital injection is planned. The acquisition is classified as a discloseable transaction under the Listing Rules, requiring reporting and announcement.

The most recent analyst rating on (HK:1501) stock is a Buy with a HK$33.68 price target. To see the full list of analyst forecasts on Shanghai Kindly Medical Instruments Co., Ltd. Class H stock, see the HK:1501 Stock Forecast page.